Compare SSTK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | FULC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.1M | 535.5M |
| IPO Year | 2012 | 2019 |
| Metric | SSTK | FULC |
|---|---|---|
| Price | $17.38 | $7.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $25.00 | $16.38 |
| AVG Volume (30 Days) | 194.0K | ★ 916.8K |
| Earning Date | 04-28-2026 | 04-27-2026 |
| Dividend Yield | ★ 8.17% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $3.55 |
| 52 Week High | $29.50 | $15.74 |
| Indicator | SSTK | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 44.20 |
| Support Level | $15.88 | $7.40 |
| Resistance Level | $17.81 | $8.24 |
| Average True Range (ATR) | 0.52 | 0.48 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 41.19 | 30.51 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.